The frontier biological Jintang base, that is, the frontier high-end peptide biopharmaceutical industrial base in Sichuan, is located in Huaizhou New City, Chengdu. It was invested and constructed by Frontier Biopharmaceutical (Nanjing) Co., Ltd. from 2065438 to February 2008, with a total investment of1400 million yuan. It is the second raw material medicine production base of China Frontier Biology, and also a modern medicine production base meeting the requirements of the national CGMP. The first phase of the project mainly includes 1 crude drug production line, polypeptide drug pilot production line, polypeptide drug preparation production line and related supporting facilities. It is estimated that the annual output of the original drug is more than 200 kilograms. The base will build a global supply chain of cutting-edge bio-high-end peptide innovative drugs, represented by Aibo Weitai, to help China's innovative drugs go abroad and go global.
It is reported that Aibo Weitai is a major national innovation jointly developed by several national key talent engineering experts. It is a national first-class new drug, the first independent innovative drug in the field of AIDS in China, and the first long-acting HIV fusion inhibitor in the world. The drug was approved by the State Administration of Pharmaceutical Products in May 20 18, and Aikening was successfully listed in the national medical insurance drug list in 2020. It is also the only long-acting anti-HIV injection drug approved to be listed in the domestic market at present, which effectively fills the clinical gap in the treatment scheme for AIDS inpatients and critically ill patients in China, breaks the monopoly of new anti-AIDS drugs by foreign pharmaceutical companies, and realizes the "zero breakthrough" of new anti-AIDS drugs in China.